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ABSTRACT  
Purpose 
While survival following colorectal cancer (CRC) has improved in countries with high CRC 
incidence, the effect of lifestyle factors on survival after diagnosis is not well established. We 
examined lifestyle factors measured before diagnosis as prognostic factors for CRC. 
Patients and Methods 
The Melbourne Collaborative Cohort Study collected data on alcohol intake, cigarette 
smoking and physical activity, and body measurements at baseline (1990-94) and wave 2 
(2003-07). We included participants diagnosed to 31 August 2015 with incident stage I-III 
CRC within 10-years post exposure assessment. Information on tumor characteristics was 
obtained from the cancer registry and histopathologic review, while vital status was obtained 
from the cancer registry and national death indices. Tumor DNA was tested for somatic 
mutations in oncogenes BRAF and KRAS. Cox regression was used to estimate hazard ratios 
(HRs) for potential prognostic factors for overall and CRC-specific mortality. 
Results 
Of 724 eligible CRC cases, 339 died (including 170 from CRC) during an average of 9.0 
years of follow-up. Exercise (non-occupational/leisure-time) was associated with better CRC-
specific survival for stage II (HR, 0.25; 95% CI, 0.10 to 0.60) but not stage I or III disease (P 
for interaction = .01), and possibly for colon and KRAS wild-type tumors. Waist 
circumference was inversely associated with CRC-specific survival (HR, 1.256 per 10 cm 
increment; 95% CI, 1.08 to 1.44), independent of stage, site and tumor molecular status. 
Cigarette smoking was associated with lower overall survival, with suggestive evidence of 
worse survival for BRAF mutated CRC, but not with CRC-specific survival. Alcohol intake 
was not associated with survival.  
Conclusion 
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We have identified pre-diagnostic predictors of survival following CRC that may have 
clinical and public health relevance.  
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INTRODUCTION 
Survival following a diagnosis of colorectal cancer (CRC) has improved in recent decades 
but a substantial proportion of those diagnosed continue to die from CRC, making it 
important to identify potential prognostic factors.1 Studies of factors associated with disease 
outcomes have predominantly examined the role of tumor characteristics, with stage at 
diagnosis being the most important prognostic factor,2 but have also evaluated potentially 
modifiable lifestyle factors such as obesity, physical activity and diet.3-6 A previous analysis 
from the Melbourne Collaborative Cohort Study (MCCS) reported that physical activity prior 
to diagnosis was associated with better overall and CRC-specific survival for patients 
diagnosed with stage II or III CRC, while increased central obesity was associated with 
poorer survival.7 While the role of smoking has been examined widely,8-14 more recent 
studies have assessed alcohol intake.10,15-19 Studies of CRC survival by tumor molecular 
characteristics have mostly used microsatellite instability (MSI) status.20  
      The present study updates and extends a previous analysis of MCCS data by including an 
additional 11 years of follow-up, additional lifestyle factors including smoking and alcohol 
intake, and survival by CRC subtype based on somatic mutations in the oncogenes BRAF 
(V600E) and KRAS (codons 12 and 13). 
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PATIENTS AND METHODS 
Study Population 
The MCCS is an Australian prospective cohort study of 41,513 people (99.2% aged 40-69 
years; 58.9% women) recruited during 1990-94 from Melbourne residents.21 At study entry 
(baseline), participants attended clinics where demographic, anthropometric, lifestyle and 
dietary information was collected and anthropometric measurements performed. Additional 
information was collected between 2003 and 2007 (wave 2). Participants gave written 
informed consent to participate and for investigators to obtain access to their medical records. 
The study protocol was approved by the Cancer Council Victoria’s Human Research Ethics 
Committee.  
      For this analysis, we selected participants who did not have a previous diagnosis of 
cancer at enrolment and had an incident CRC diagnosed during follow-up, within 10 years of 
exposure assessment at baseline or wave 2 (Appendix Fig A1). Individuals with metastatic 
disease (stage IV) were excluded for greater comparability with previous studies22-24 and to 
minimize potential effects of reverse causation such as undiagnosed advanced disease 
altering lifestyle patterns before diagnosis. Participants who had a CRC diagnosed less than 6 
months after exposure assessment were also excluded. CRC cases were defined as having a 
first histopathological diagnosis of adenocarcinoma of the colon or rectum reported to the 
Victorian Cancer Registry (VCR), coded following the 3rd Revision of the International 
Classification of Diseases for Oncology (ICD-O-3) as colon (C180, C182-189) or rectum 
(C199, C209). Carcinomas of the appendix, anus and anal canal (including overlapping 
lesions of rectum, anus and anal canal) were excluded. In-situ lesions were also excluded. 
Participants with metachronous CRC were censored at the time of diagnosis of the second 
primary CRC for the CRC-specific survival analysis. Tumor site, stage and degree of 
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differentiation were obtained from VCR and standardized review of archival tumor tissue by 
a gastrointestinal histopathologist (CR).  
 
Assessment of Demographic Information, Alcohol Intake, Smoking and Physical 
Activity 
Structured interview schedules were used at baseline to obtain demographic information, and 
at both waves to collect information about alcohol intake, smoking and physical activity. At 
baseline, participants were asked whether they smoked at least seven cigarettes a week, and if 
so, the number of cigarettes they smoked per day and the duration of smoking. At wave 2, 
smokers at baseline were asked if they were still smoking, and if so the amount smoked. 
Alcohol intake for non-abstainers was recorded as frequency and quantity of intake per 
drinking occasion, for beer, wine and spirits, for decades of age starting from 20 years. 
Detailed information on the method of calculating lifetime intake (g/day) at baseline has been 
reported previously;25 at wave 2, intake during the previous year was assessed similarly. 
Physical activity at baseline was assessed by three separate questions regarding frequency of 
non-occupational vigorous and moderate physical activity, and walking, as described by 
Haydon et al.7 Those who answered ‘not at all’ to vigorous and moderate physical activity 
were classified as ‘non-exercisers’ while those who reported any regular exercise (≥1 time 
per week) were classified as ‘exercisers’. Individuals were classified as ‘walkers’ if they 
walked for recreation and/or exercise at least once a week over the last six months, while 
individuals were classified as ‘non-walkers’ if they answered ‘not at all’ to all three physical 
activity questions. Additionally, the responses to each question were coded as 0 (‘none’), 1.5 
(1-2 per week) and 4 (≥3 per week). Scores for walking and moderate exercise were added 
together along with two times the score for vigorous exercise to generate a physical activity 
score for each participant. A modified form of the long version of the International Physical 
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Activity Questionnaire (available at www.ipaq.ki.se) was used at wave 2.26 It includes 
questions about duration and frequency of vigorous and moderate physical activity, and 
walking.  
  
Assessment of Body Composition 
Height was measured at baseline to 1 mm with a stadiometer. At both baseline and wave 2, 
weight was measured to 100 g using digital electronic scales and waist circumferences to 1 
mm using a two-meter metal anthropometric tape.27  
 
Tumor Characterization 
The American Joint Committee on Cancer (AJCC) staging system was used to categorize 
stage: stage I (T1–2, N0, M0), stage II (T3–4, N0, M0) and stage III (Tany, N1–2, M0). The tumor 
with the highest stage was used when synchronous CRCs were present. The degree of tumor 
differentiation was classified as ‘well’, ‘moderately’ and ‘poorly’ differentiated. Separate 
categories were used for cases with missing stage and degree of differentiation. For tumors 
diagnosed by June 2009, we attempted to obtain archival tumor tissue and to test tumor DNA 
for the V600E mutation in BRAF, which accounts for approximately 90% of BRAF mutations 
in colorectal cancer,28 using a fluorescent allele-specific PCR discrimination method as 
previously described29 and for mutations in exon 2 of KRAS by direct Sanger sequencing.30  
     
Ascertainment of Deaths and Cause of Death 
Vital status was ascertained through the VCR and the National Death Index (NDI). Cause of 
death was assigned as reported in the NDI and VCR.            
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Statistical Analysis 
We used Cox regression31 with time since CRC diagnosis as the time axis to estimate hazard 
ratios (HR) and 95% confidence intervals (CI) for overall and CRC-specific mortality. 
Analysis time began at date of diagnosis and ended at death or 31 August 2015 (the date at 
which ascertainment of deaths was complete), whichever came first. For CRC-specific 
survival, individuals were censored at death when the cause of death was anything other than 
CRC, but were excluded when no information was available on cause of death. Lifestyle 
factors included current and past alcohol intake (continuous: per 10 g/day increment; 
categorical: lifetime abstention, former drinker, >0-19, 20-39, ≥40 g/day), cigarette smoking 
status (categorical: never, former, current smokers), number of cigarettes (categorical: 0, 1-
10, 11-20, ≥21 per day), duration of smoking (categorical: 0, >0-15, 16-30, ≥31 years), time 
since quitting (categorical: <10, ≥10 years), physical activity (categorical: score 0, >0-3.9, 
≥4-5.9, ≥6), exercising (categorical: non-exercisers, exercisers), walking (categorical: non-
walkers, walkers), BMI (continuous: per 5 kg/m2; categorical: normal <25 kg/m2, overweight 
25-29 kg/m2, obese ≥30 kg/m2),32 and waist circumference (continuous: per 10 cm; 
categorical: healthy <94 cm for males, <80 cm for females; action levels ≥94 cm for males, 
≥80 cm for females).33 Baseline exposure data were used for participants diagnosed with 
CRC within 10 years post study enrolment whereas wave 2 exposure data were used for 
particpants diagnosed with CRC within 10 years post wave 2. All multivariate models were 
adjusted for age at diagnosis of CRC (categorical: <60, 60-69, ≥70 years), year of diagnosis 
(categorical: <1999, 1999-2005, ≥2006), sex and the country of birth (Australia/United 
Kingdom, Italy/Greece). We repeated the analyses adjusting additionally for AJCC stage 
(categorical: stage I, stage II, stage III), degree of differentiation (categorical: 
well/moderately, poorly differentiated) and anatomic site (colon, rectum), potential mediators 
of associations between the lifestyle factors and survival following CRC. A sensitivity 
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analysis performed to account for potential effects of reverse causation excluded participants 
with pre-existing diagnosis of heart attack, stroke, angina or diabetes. A subgroup analysis 
was performed to test differences in associations by BRAF and KRAS status for participants 
for whom tumor molecular data were available. We fitted interaction terms to test for 
differences in HRs for each lifestyle factor by stage, anatomic site, and BRAF and KRAS 
status. We compared nested models using the likelihood ratio test. We examined each model 
for outliers and influential points and used Schoenfeld residuals to assess the proportional 
hazard assumptions; there was no evidence that they were violated. All statistical analyses 
were performed using Stata 14.1 (StataCorp, College Station, TX).     
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RESULTS 
Among eligible MCCS participants with no previous diagnosis of cancer at enrolment, 1,227 
incident CRC cases were diagnosed. We excluded 43 diagnosed less than 6 months and 269 
diagnosed more than 10 years after exposure measurement exposure measurement, 157 with 
stage IV disease and 34 with missing information on covariates, leaving 724 CRC cases (467 
colon, 257 rectal) for the overall survival analysis (Appendix Fig A2). The median time from 
exposure measurement to CRC diagnosis was 4.9 years, and the average follow-up from CRC 
diagnosis was 9.0 years. During follow-up, 339 deaths occurred, of which 170 (50%) were 
CRC-specific; cause of death was unknown for 26. Characteristics of participants included in 
the analysis are shown in Table 1. Participants with unknown tumor molecular data did not 
differ from others in terms of age, sex or ethnicity (data not shown).  
      HR estimates for overall and CRC-specific mortality are shown in Table 2 and Table 3, 
respectively. Lifetime and past alcohol intakes were not associated with survival. Current 
alcohol intake was associated with better CRC-specific survival (i.e. lower mortality) (HR, 
0.90 per 10 g/day increment; 95% CI, 0.82 to 0.99); the HR was 0.91 per 10 g/day increment 
(95% CI, 0.83 to 1.01) when former drinkers were excluded (data not shown). Cigarette 
smoking was not associated with CRC-specific survival although lower CRC-specific 
survival was evident for former smokers who quit ≥10 years ago (HR, 1.92; 95% CI, 1.04 to 
3.55). A dose-dependent association between smoking and overall survival was observed (P 
for trend = .04 for number of cigarettes smoked per day). Higher waist circumference was 
associated with lower overall and CRC-specific survival (e.g. HR, 1.25 per 10 cm increment; 
95% CI, 1.08 to 1.44 for CRC-specific survival); the association for BMI with survival was 
less clear (HR, 1.18 per 5 kg/m2 increment; 95% CI, 0.98 to 1.42 for CRC-specific survival). 
Measures of physical activity were not associated with survival in this analysis. These 
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associations did not materially change when adjusted for primary CRC-related features, or 
when participants with pre-existing disease were excluded (Appendix Table A1).  
      Exercise prior to diagnosis was associated with improved CRC-specific survival for those 
diagnosed with stage II (HR, 0.25; 95% CI, 0.10 to 0.60) but not with stage I or III CRC (P 
for interaction = .01) (Table 4; additional results are shown in Appendix Table A2). There 
was also suggestive evidence that the better disease-specific survival in relation to exercise 
prior to diagnosis was limited to colon cancer (HR, 0.68; 95% CI, 0.44 to 1.05; P for 
interaction = .09) (Table 5) and to KRAS wild-type CRC (HR, 0.61; 95% CI, 0.38 to 0.98; P 
for interaction = .1) (Fig 1; Appendix Table A4). These associations were stronger after 
adjustment for primary CRC-related features (Appendix Table A3; Appendix Table A5). 
Differential survival observed for walking (lowest overall survival observed for stage III: HR, 
1.84; 95% CI, 1.10 to 3.08; P for interaction = .01) was not evident when participants with 
existing illnesses were excluded (P for interaction = .2); excluding participants with existing 
illnesses did not change results for exercise (HR, 0.22; 95% CI, 0.08 to 0.57 for stage II CRC; 
P for interaction = .002 for CRC-specific survival) (data not shown).  
      There was weak evidence of approximately a two-fold lower survival for smokers with 
BRAF mutated CRC (HR, 1.82; 95% CI, 0.99 to 3.36; P for interaction = .08) (Fig 1; 
Appendix Table A4).  
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DISCUSSION 
While lower CRC-specific survival was observed for individuals who were obese prior to 
CRC diagnosis, exercise was only associated with better disease-specific survival for stage II 
disease, and possibly, colon cancer and KRAS wild-type tumors. Although cigarette smoking 
prior to CRC diagnosis was associated with lower overall survival with suggestive evidence 
of worse survival for BRAF mutated CRC, smoking was not associated with CRC-specific 
survival. Pre diagnosis alcohol intake was not related to survival.  
      Smoking, a known risk factor34 especially for BRAF mutated and MSI-high CRC 
incidence,35 is a strong determinant of mortality.36 The absence of an association with CRC-
specific survival in our study contrasts with evidence from the North Central Cancer 
Treatment Group Phase III Trial N0147 which found adverse disease-free survival for 
smoking for BRAF wild-type and KRAS mutated colon cancer.14 However, the definition of 
survival outcome was different (time to colon cancer recurrence or death from any cause) and 
the study included only participants with stage III colon cancer.14 Using the same cohort of 
clinical trial participants, authors observed a potentially beneficial effect on survival from 
wine intake with no association for drinking overall.16 Long term alcohol intake is associated 
with a ~50% higher risk of CRC,37 but evidence for differential risks by anatomic location38-
40 or by molecular subtype (MSI;41-45 BRAF and CIMP46,47) has been inconsistent. The 
absence of an association between lifetime alcohol intake and survival in our study is 
consistent with existing evidence for alcohol.10,15,17,18 We believe that the apparent CRC-
specific survival benefit seen for current intake in our study may have been influenced by the 
inclusion of ‘sick quitters’ within abstainers.48 Authors of a recent analysis of a large 
population-based German cohort19 discussed the possible contamination of abstainers with 
‘sick quitters’ as a possible explanation for poorer CRC-specific survival seen for abstainers 
among nonmetastatic CRC patients with current as well as lifetime intake; Rehm et al. have 
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shown that using lifetime abstention as the reference category may not completely avoid 
contamination.49 
      Our findings for obesity and exercise are biologically plausible and replicate existing 
evidence6,13,22-24,50,51 considering the inverse relationship between the two. Among the 
postulated biological explanations for an association between obesity and survival following 
CRC are increased insulin resistance,3 inflammation and oxidative stress, and impaired 
immune surveillance,52 factors which might also be related to CRC incidence. On the other 
hand, physical activity favorably affects survival following CRC via increased insulin-like 
growth factor binding proteins,3,53 and by modulating oxidative DNA damage.54 We 
replicated our previous findings for a detrimental association between obesity and survival 
following CRC that is more evident with waist circumference than with BMI, and for 
differential associations with exercise, which most likely differentiated those who were 
physically active from those who were not in our data, by disease stage.7 Contrary to others, 
we did not observe differential survival for obesity by disease stage.5,50 We speculate that 
evidence of differential survival by disease stage for walking status that diminished when 
participants with existing illness were excluded may have been due to reverse causation.  
      Our finding suggestive of a greater survival benefit from exercise for colon but not rectal 
cancer is in line with findings from the Seattle Colon Cancer Family Registry,22 and may 
reflect a greater diagnostic delay and symptomatic disease at the time of diagnosis for rectal 
cancer.55 Existing evidence for differential survival by anatomic site for obesity is 
inconsistent,5,51,56 and we did not observe any.  
      Few findings have been reported for subtypes defined by somatic mutations in oncogenes. 
Evidence of an association between obesity and the risk of BRAF mutated or CIMP+ CRC 
(which is highly correlated with somatic mutations in BRAF) is inconsistent.57,58 It is possible 
that we may not have observed lower survival associated with obesity for BRAF mutated 
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CRC in the present study due to the exclusion of stage IV tumors (stage IV tumors and BRAF 
mutated CRC have worse survival59). We observed weak evidence suggestive of a survival 
benefit of exercise that was limited to KRAS wild-type CRC. The only comparable study that 
has considered subtypes based on BRAF and KRAS status did not observe evidence of 
differential survival.22 BRAF and KRAS are routinely assessed for screening for Lynch 
syndrome and for assessing response to therapy, respectively,60,61 and any potential survival 
benefit for KRAS wild-type CRC could have important clinical implications.  
      Strengths of this analysis include: prospective design; near complete follow-up; relatively 
large number of deaths; and availability of detailed information on lifestyle factors. This 
study also contributes to a sparse literature by examining the relationship between alcohol 
intake and survival following CRC10 and by evaluating survival by BRAF and KRAS 
status:14,22 the etiology of each CRC is unique62-64  
      There are several limitations. First, the unavailability of full details of treatment has 
prevented the evaluation of treatment as an effect modifier but disease stage is highly 
correlated with treatment. Second, we addressed the issue of reverse causation by excluding 
individuals with metastatic disease, who had a CRC diagnosed less than 6 months after 
exposure assessment, and, in a sensitivity analysis, with pre-existing illness prior to CRC 
diagnosis although ill health altering lifestyle patterns before CRC cannot be excluded 
completely. Third, measurement error and misclassification of alcohol intake, and inaccuracy 
of self-reported physical activity measurement may have attenuated associations. Fourth, 
archival tissue from the CRC was unavailable for a substantial number of cases. However, 
this may not have biased the observed associations by BRAF and KRAS status as cases with 
and without tumor molecular data varied little by demographic characteristics such as 
ethnicity and sex which were both strongly associated with molecular subtype. Finally, 
misclassification of underlying cause of death is also possible.   
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      In conclusion, smoking, exercise and obesity are not only risk factors for CRC, but are 
associated with survival after diagnosis. Future research is necessary to determine whether 
exercising, losing weight and smoking cessation after diagnosis affect survival, and to 
examine underlying biological and molecular pathological mechanisms underpinning these 
associations. 
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Table 1. Characteristics for CRC cases in the Melbourne Collaborative Cohort Study, for all cases and according to smoking status, exercising 
and waist circumference 
 All cases 
 
(n=724) 
Cigarette smoking Exercising Waist circumferencea 
Ever smokers 
(n=350) 
Never-
smokers  
(n=374) 
Exercisers  
(n=319) 
Non-exercisers  
(n=405) 
Healthy  
(n=259) 
Action level  
(n=465) 
Age at diagnosis (years)        
   Median (range) 71 (44-87) 70 (44-87) 71 (44-87) 71 (45-87) 70 (44-87) 70 (44-87) 71 (45-87) 
Sex (n, %)        
   Male 357 (49.3) 231 (66.0) 126 (33.7) 154 (48.3) 203 (50.1) 122 (47.1) 235 (50.5) 
   Female 367 (50.7) 119 (34.0) 248 (66.3) 165 (51.7) 202 (49.9) 137 (52.9) 230 (49.5) 
Country of birth (n, %)          
   Australia/United Kingdom 585 (80.8) 279 (79.7) 306 (81.8) 277 (86.8) 308 (76.1) 226 (87.3) 359 (77.2) 
   Italy/Greece 139 (19.2) 71 (20.3) 68 (18.2) 42 (13.2) 97 (23.9) 33 (12.7) 106 (22.8) 
AJCC stage (n, %)        
   Stage I 200 (27.6) 105 (30.0) 95 (25.4) 84 (26.3) 116 (28.6) 72 (27.8) 128 (27.5) 
   Stage II 251 (34.7) 121 (34.6) 130 (34.8) 109 (34.2) 142 (35.1) 88 (34.0) 163 (35.1) 
   Stage III 232 (32.0) 101 (28.9) 131 (35.0) 107 (35.5) 125 (30.9) 85 (32.8) 147 (31.6) 
   Unknown 41 (5.7) 23 (6.6) 18 (4.8) 19 (6.0) 22 (5.4) 14 (5.4) 27 (5.8) 
Degree of differentiation (n, %)        
   Well 21 (2.9) 13 (3.7) 8 (2.1) 11 (3.4) 10 (2.5) 10 (3.9) 11 (2.4) 
   Moderate 466 (64.4) 219 (62.6) 247 (66.1) 205 (64.3) 261 (64.4) 163 (62.9) 303 (65.2) 
   Poor 163 (22.5) 74 (21.1) 89 (23.8) 72 (22.6) 91 (22.5) 62 (23.9) 101 (21.7) 
   Unknown 74 (10.2) 44 (12.6) 30 (8.0) 31 (9.7) 43 (10.6) 24 (9.3) 50 (10.7) 
Anatomic site        
   Colon 467 (64.5) 223 (63.7) 244 (65.2) 201 (63.0) 266 (65.7) 161 (62.2) 306 (65.8) 
   Rectum 257 (35.5) 127 (36.3) 130 (34.8) 118 (37.0) 139 (34.3) 98 (37.8) 159 (34.2) 
BRAF status        
   BRAF wild-type 383 (52.9) 186 (53.1) 197 (52.7) 167 (52.3) 216 (53.3) 151 (58.3) 232 (49.9) 
   BRAF mutated 82 (11.3) 39 (11.2) 43 (11.5) 42 (13.2) 40 (9.9) 31 (12.0) 51 (11.0) 
   Unknown 259 (35.8) 125 (35.7) 134 (35.8) 110 (34.5) 149 (36.8) 77 (29.7) 182 (39.1) 
KRAS status        
   KRAS wild-type  335 (46.3) 160 (45.7) 175 (46.8) 145 (45.4) 190 (46.9) 130 (50.2) 205 (44.1) 
   KRAS mutated 131 (18.1) 67 (19.1) 64 (17.1) 65 (20.4) 66 (16.3) 53 (20.5) 78 (16.8) 
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   Unknown 258 (35.6) 123 (35.2) 135 (36.1) 109 (34.2) 149 (36.8) 76 (29.3) 182 (39.1) 
Lifetime alcohol intake (n, %)b        
   Mean (SD) (g/day) 19.5 (21.9) 24.3 (23.9) 13.2 (17.2) 18.9 (21.2) 20.0 (22.5) 18.2 (20.1) 20.2 (22.8) 
Cigarette smoking (n, %)        
   Never 374 (51.7) - - 169 (53.0) 205 (50.6) 135 (52.1) 239 (51.4) 
   Former 289 (39.9) - - 130 (40.7) 159 (39.3) 97 (37.5) 192 (41.3) 
   Current 61 (8.4) - - 20 (6.3) 41 (10.1) 27 (10.4) 34 (7.3) 
Exercising (n, %)          
   Non-exercisers 405 (55.9) 200 (57.1) 205 (54.8) - - 125 (48.3) 280 (60.2) 
   Exercisers 319 (44.1) 150 (42.9) 169 (45.2) - - 134 (51.7) 185 (39.8) 
Walking (n, %)c          
   Non-walkers 132 (20.8) 68 (21.9) 64 (19.7) 0 (0.0) 132 (32.6) 47 (21.4) 85 (20.5) 
   Walkers 503 (79.2) 243 (78.1) 260 (80.3) 230 (100.0) 273 (67.4) 173 (78.6) 330 (79.5) 
BMI (n, %)        
   <25 kg/m2 206 (28.4) 98 (28.0) 108 (28.9) 104 (32.6) 102 (25.2) 162 (62.6) 44 (9.5) 
   25-29 kg/m2 354 (48.9) 173 (49.4) 181 (48.4) 161 (50.5) 193 (47.6) 92 (35.5) 262 (56.3) 
   ≥30 kg/m2 164 (22.7) 79 (22.6) 85 (22.7) 54 (16.9) 110 (27.2) 5 (1.9) 159 (34.2) 
Waist circumference (n, %)        
   Healthy  259 (35.8) 124 (35.4) 135 (36.1) 134 (42.0) 125 (30.9) - - 
   Action level  465 (64.2) 226 (64.6) 239 (63.9) 185 (58.0) 280 (69.1) - - 
SD, standard deviation; BMI, body mass index; AJCC, American Joint Committee on Cancer. 
aWaist circumference: healthy, <94 cm for males and <80 cm for females; action level, ≥94 cm for males and ≥80 cm for females. 
bExcluding lifetime abstainers (n=183). 
cPeople who only reported exercising were excluded.  
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Table 2 Hazard ratios (HR) and 95% confidence intervals (CI) for overall mortality by 
alcohol intake, cigarette smoking, physical activity, exercise, walking, BMI and waist 
circumference  
 No. No. of 
events 
Primary modela Model adjusted for primary 
CRC-related featuresb 
HR 95% CI HR 95% CI 
Alcohol intake        
   Lifetime intake (per 10 g/day) 724 339 1.01 0.95 to 1.07 1.03 0.97 to 1.09 
   P value   0.8  0.3  
   Current intake (per 10 g/day) 724 339 0.97 0.91 to 1.03 0.97 0.91 to 1.03 
   P value   0.3  0.3  
      Lifetime abstention 183 89 Reference  Reference  
      Former drinkers 82 40 1.10 0.74 to 1.63 1.30 0.87 to 1.93 
      >0-19 g/day 281 126 0.86 0.64 to 1.14 0.99 0.74 to 1.33 
      20-39 g/day 103 49 0.96 0.66 to 1.40 1.04 0.71 to 1.53 
      ≥40 g/day 75 35 0.80 0.52 to 1.23 0.89 0.58 to 1.38 
      P for trendc   0.4  0.8  
   Age 20-29 intake (per 10 g/day) 724 339 1.02 0.97 to 1.07 1.04 0.99 to 1.09 
   P value   0.5  0.2  
   Age 30-39 intake (per 10 g/day) 724 339 1.01 0.96 to 1.06 1.03 0.98 to 1.08 
   P value   0.8  0.3  
   Age 40-49 intake (per 10 g/day) 724 339 1.02 0.97 to 1.06 1.03 0.98 to 1.08 
   P value   0.5  0.2  
Cigarette smoking         
   Smoking status       
      Never 374 154 Reference  Reference  
      Ever 350 185 1.27 1.00 to 1.60 1.32 1.04 to 1.67 
      P for trend   0.05  0.02  
   Smoking status       
      Never 374 154 Reference  Reference  
      Former 289 153 1.25 0.98 to 1.59 1.29 1.01 to 1.65 
      Current 61 32 1.37 0.92 to 2.05 1.44 0.96 to 2.15 
   Number of cigarettes per day       
      0 374 154 Reference  Reference  
      1-10  111 54 1.17 0.85 to 1.61 1.22 0.89 to 1.68 
      11-20 140 78 1.36 1.02 to 1.82 1.37 1.02 to 1.83 
      ≥21 95 52 1.33 0.93 to 1.88 1.49 1.04 to 2.13 
      Unknown 4 1 -  -  
      P for trend   0.04  0.01  
   Duration of smoking (years)         
      0 374 154 Reference  Reference  
      >0-15 67 34 1.24 0.85 to 1.83 1.26 0.86 to 1.85 
      16-30 116 58 1.20 0.87 to 1.66 1.46 1.05 to 2.03 
      ≥31 167 93 1.32 0.99 to 1.74 1.26 0.95 to 1.67 
      P for trend   0.05  0.05  
   Time since quitting (years)d       
      <10  70 33 Reference  Reference  
      ≥10 219 120 1.31 0.88 to 1.97 1.48 0.98 to 2.23 
      P for trend   0.2  0.06  
Physical activity       
   Physical activity score        
      0 132 72 Reference  Reference  
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      >0-3.9 112 46 0.85 0.58 to 1.24 0.89 0.61 to 1.31 
      ≥4-5.9 313 147 0.96 0.71 to 1.29 0.93 0.69 to 1.26 
      ≥6 167 74 0.86 0.61 to 1.21 0.86 0.61 to 1.21 
      P for trend   0.4  0.6  
   Exercising          
      Non-exercisers 405 197 Reference  Reference  
      Exercisers 319 142 0.86 0.69 to 1.07 0.84 0.67 to 1.05 
     P for trend   0.2  0.1  
   Walkinge        
      Non-walkers 132 72 Reference  Reference  
      Walkers 503 231 0.95 0.72 to 1.27 0.95 0.71 to 1.26 
      P for trend   0.7  0.7  
Body size        
   BMI (per 5 kg/m2) 724 339 1.14 0.99 to 1.30 1.13 0.99 to 1.29 
   P value   0.06  0.08  
      Normal 206 89 Reference  Reference  
      Overweight 354 175 1.22 0.94 to 1.60 1.39 1.06 to 1.82 
      Obese 164 75 1.17 0.85 to 1.61 1.14 0.82 to 1.56 
      P for trend   0.2  0.3  
   Waist circumferencef (per 10 cm)  724 339 1.19 1.07 to 1.32 1.18 1.06 to 1.31 
   P value   0.001  0.002  
      Healthy 259 112 Reference  Reference  
      Action levels 465 227 1.24 0.98 to 1.56 1.29 1.02 to 1.64 
      P for trend   0.07  0.03  
aAdjusted for age at diagnosis, year of diagnosis, sex and country of birth in addition to the 
exposures shown in the table. 
bAdjusted for age at diagnosis, year of diagnosis, sex, country of birth, American Joint 
Committee on Cancer stage, degree of differentiation and anatomic site in addition to the 
exposures shown in the table. 
cCalculated excluding former drinkers.  
dIncludes only former smokers. 
ePeople who only reported exercising were excluded.  
fWaist circumference categorized as healthy (<94 cm for males; <80 cm for females) and 
action levels (≥94 cm for males; ≥80 cm for females). 
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Table 3 Hazard ratios (HR) and 95% confidence intervals (CI) for CRC-specific mortality by 
alcohol intake, cigarette smoking, physical activity, exercise, walking, BMI and waist 
circumference  
 No. No. of 
events 
Primary modela Model adjusted for primary 
CRC-related featuresb 
HR 95% CI HR 95% CI 
Alcohol intake        
   Lifetime intake (per 10 g/day) 698 170 0.97 0.89 to 1.05 0.99 0.91 to 1.08 
   P value   0.4  0.8  
   Current intake (per 10 g/day) 698 170 0.90 0.82 to 0.99 0.88 0.79 to 0.98 
   P value   0.03  0.02  
      Lifetime abstention 177 46 Reference  Reference  
      Former drinkers 80 24 1.24 0.73 to 2.08 1.50 0.89 to 2.53 
      >0-19 g/day 268 63 0.80 0.54 to 1.21 0.92 0.61 to 1.39 
      20-39 g/day 100 24 0.81 0.47 to 1.39 0.86 0.50 to 1.47 
      ≥40 g/day 73 13 0.55 0.28 to 1.06 0.57 0.29 to 1.13 
      P for trendc   0.09  0.2  
   Age 20-29 intake (per 10 g/day) 698 170 0.98 0.91 to 1.06 1.01 0.94 to 1.08 
   P value   0.7  0.8  
   Age 30-39 intake (per 10 g/day) 698 170 0.99 0.93 to 1.06 1.02 0.95 to 1.09 
   P value   0.8  0.6  
   Age 40-49 intake (per 10 g/day) 698 170 0.98 0.91 to 1.05 1.00 0.93 to 1.08 
   P value   0.5  0.9  
Cigarette smoking         
   Smoking status       
      Never 366 81 Reference  Reference  
      Ever 332 89 1.28 0.92 to 1.79 1.34 0.96 to 1.86 
      P for trend   0.1  0.09  
   Smoking status       
      Never 366 81 Reference  Reference  
      Former 274 76 1.33 0.94 to 1.88 1.37 0.97 to 1.93 
      Current 58 13 1.07 0.58 to 1.96 1.18 0.64 to 2.17 
   Number of cigarettes per day       
      0 366 81 Reference  Reference  
      1-10  104 31 1.48 0.96 to 2.28 1.47 0.96 to 2.27 
      11-20 134 36 1.25 0.82 to 1.89 1.25 0.82 to 1.90 
      ≥21 91 22 1.11 0.66 to 1.85 1.33 0.78 to 2.25 
      Unknown 3 0 -  -  
      P for trend   0.4  0.2  
   Duration of smoking (years)         
      0   Reference  Reference  
      >0-15 366 81 1.63 0.99 to 2.67 1.65 1.00 to 2.71 
      16-30 63 21 1.10 0.69 to 1.76 1.49 0.92 to 2.39 
      ≥31 111 27 1.26 0.84 to 1.89 1.14 0.76 to 1.72 
      P for trend 158 41 0.3  0.4  
   Time since quitting (years)d       
      <10  68 13 Reference  Reference  
      ≥10 206 63 1.92 1.04 to 3.55 2.29 1.21 to 4.31 
      P for trend   0.04  0.01  
Physical activity       
   Physical activity score        
      0 124 34 Reference  Reference  
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      >0-3.9 109 21 0.88 0.50 to 1.53 0.97 0.55 to 1.69 
      ≥4-5.9 304 77 1.13 0.74 to 1.72 1.08 0.71 to 1.66 
      ≥6 161 38 1.04 0.64 to 1.69 1.09 0.67 to 1.78 
      P for trend   0.5  0.6  
   Exercising          
      Non-exercisers 387 99 Reference  Reference  
      Exercisers 311 71 0.88 0.64 to 1.20 0.83 0.61 to 1.14 
     P for trend   0.4  0.3  
   Walkinge        
      Non-walkers 124 34 Reference  Reference  
      Walkers 485 113 1.06 0.71 to 1.60 1.07 0.71 to 1.61 
      P for trend   0.8  0.7  
Body size        
   BMI (per 5 kg/m2) 698 170 1.18 0.98 to 1.42 1.19 0.99 to 1.43 
   P value   0.08  0.06  
      Normal 196 39 Reference  Reference  
      Overweight 343 87 1.33 0.90 to 1.97 1.65 1.10 to 2.46 
      Obese 159 44 1.39 0.88 to 2.17 1.41 0.90 to 2.21 
      P for trend   0.1  0.1  
   Waist circumferencef (per 10 cm)  698 170 1.25 1.08 to 1.44 1.26 1.09 to 1.45 
   P value   0.002  0.001  
      Healthy 247 53 Reference  Reference  
      Action levels 451 117 1.35 0.97 to 1.89 1.52 1.08 to 2.14 
      P for trend   0.08  0.02  
aAdjusted for age at diagnosis, year of diagnosis, sex and country of birth in addition to the 
exposures shown in the table. 
bAdjusted for age at diagnosis, year of diagnosis, sex, country of birth, American Joint 
Committee on Cancer stage, degree of differentiation and anatomic site in addition to the 
exposures shown in the table. 
cCalculated excluding former drinkers.  
dIncludes only former smokers. 
ePeople who only reported exercising were excluded.  
fWaist circumference categorized as healthy (<94 cm for males; <80 cm for females) and 
action levels (≥94 cm for males; ≥80 cm for females). 
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Table 4. Hazard ratios (HR) and 95% confidence intervals (CI) for overall and CRC-specific mortality by alcohol intake, cigarette smoking, 
physical activity, exercise, walking, BMI and waist circumference, by AJCC stage  
 
 Stage I Stage II Stage III  
HRa  95% CI HRa 95% CI HRa 95% CI P for interaction 
Overall mortality        
Lifetime alcohol intake (per 10 g/day) 1.12 1.02 to 1.23 1.01 0.92 to 1.12 0.99 0.91 to 1.08 0.1 
Ever smokers 1.16 0.70 to 1.93 1.28 0.85 to 1.91 1.45 1.01 to 2.07 0.8 
Physical activity score ≥4 0.83 0.50 to 1.38 0.85 0.57 to 1.26 1.13 0.78 to 1.65 0.5 
Exercisers 0.96 0.58 to 1.58 0.60 0.40 to 0.90 0.91 0.64 to 1.28 0.2 
Walkersb 0.65 0.37 to 1.15 0.75 0.47 to 1.18 1.84 1.10 to 3.08 0.01 
BMI (per 5 kg/m2) 1.21 0.90 to 1.62 1.17 0.91 to 1.51 1.14 0.94 to 1.39 0.9 
Waist circumference (per 10 cm)  1.24 1.02 to 1.52 1.26 1.06 to 1.49 1.11 0.96 to 1.29 0.4 
        
CRC-specific mortality        
Lifetime alcohol intake (per 10 g/day) 1.13 0.96 to 1.34 0.94 0.78 to 1.13 0.98 0.88 to 1.09 0.3 
Ever smokers 1.31 0.46 to 3.74 1.40 0.71 to 2.75 1.44   0.94 to 2.20 0.9 
Physical activity score ≥4 0.80 0.28 to 2.26 0.85 0.43 to 1.67 1.18 0.76 to 1.85 0.6 
Exercisers 0.88 0.31 to 2.49 0.25 0.10 to 0.60 0.98 0.65 to 1.46 0.01 
Walkersb 0.64 0.19 to 2.13 0.67 0.32 to 1.38 1.83 0.98 to 3.42 0.07 
BMI (per 5 kg/m2) 1.71 0.95 to 3.06 1.19 0.78 to 1.79 1.18 0.94 to 1.49 0.5 
Waist circumference (per 10 cm)  1.88 1.22 to 2.90 1.28 0.97 to 1.69 1.19 0.99 to 1.42 0.1 
BMI, body mass index. 
aAdjusted for age at diagnosis, year of diagnosis, sex and country of birth in addition to the exposures shown in the table. 
bPeople who only reported exercising were excluded. 
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Table 5. Hazard ratios (HR) and 95% confidence intervals (CI) for overall and disease-specific mortality by alcohol intake, cigarette smoking, 
physical activity, exercise, walking, BMI and waist circumference, by anatomic site  
 
 Colon Rectum  
HRa  95% CI HRa 95% CI P for interaction 
Overall mortality      
Lifetime alcohol intake (per 10 g/day) 1.01 0.94 to 1.08 1.00 0.92 to 1.09 0.9 
Ever smokers 1.47 1.10 to 1.97 1.01 0.70 to 1.44 0.1 
Physical activity score ≥4 1.01 0.75 to 1.37 0.99 0.69 to 1.42 0.9 
Exercisers 0.78 0.59 to 1.04 1.00 0.70 to 1.42 0.3 
Walkersb 0.98 0.67 to 1.42 0.92 0.61 to 1.41 0.8 
BMI (per 5 kg/m2) 1.11 0.94 to 1.31 1.22 0.97 to 1.53 0.5 
Waist circumference (per 10 cm)  1.20 1.06 to 1.35 1.19 1.02 to 1.39 0.9 
      
Disease-specific mortality      
Lifetime alcohol intake (per 10 g/day) 0.99 0.89 to 1.10 0.93 0.82 to 1.05 0.4 
Ever smokers 1.47 0.95 to 2.27 1.09 0.69 to 1.74 0.3 
Physical activity score ≥4 1.32 0.82 to 2.12 1.09 0.68 to 1.75 0.6 
Exercisers 0.68 0.44 to 1.05 1.18 0.74 to 1.86 0.09 
Walkersb 1.46 0.78 to 2.73 0.86 0.49 to 1.49 0.2 
BMI (per 5 kg/m2) 1.17 0.92 to 1.48 1.23 0.93 to 1.63 0.8 
Waist circumference (per 10 cm)  1.31 1.10 to 1.56 1.21 1.00 to 1.48 0.5 
BMI, body mass index. 
aAdjusted for age at diagnosis, year of diagnosis, sex and country of birth in addition to the exposures shown in the table. 
bPeople who only reported exercising were excluded. 
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Fig 1. Kaplan-Meier curves for (A) overall survival for cigarette smoking by BRAF status and (B) CRC-specific survival for exercise by KRAS 
status.  
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Appendix 
 
 
 
Fig A1. Diagram showing exposure ascertainment and colorectal cancer (CRC) diagnosis for 
Melbourne Collaborative Cohort Study participants.    
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Fig A2. Flow diagram showing selection of participants. 
 
 
 
 
 
 
 
 
 
N=724 included in the analysis for 
overall survival  
(467 colon; 257 rectal)  
Reasons for exclusion: 
1. CRC cases diagnosed over 10 years 
after exposure measurement (n=269)  
2. CRC cases diagnosed within 6 
months of exposure measurement 
(n=43) 
3. Stage IV disease (n=157) 
4. Missing data on covariates (n=34) 
 
Among 41,513 MCCS participants, 
1,227 incident CRC cases diagnosed 
in people with no previous diagnosis 
of cancer 
N=698 included in the analysis for 
CRC-specific survival  
(443 colon; 255 rectal)  
 
Reason for exclusion: 
1. No information on cause of death 
(n=26) 
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Table A1. Hazard ratios (HR) and 95% confidence intervals (CI) for overall and CRC-
specific mortality by alcohol intake, cigarette smoking, physical activity, exercise, walking, 
BMI and waist circumference for participants with no pre-existing illness*  
 Overall mortality CRC-specific mortality 
No. No. of 
events 
HRa 95% CI  No. No. of 
events 
HRa 95% CI 
Alcohol intake          
   Lifetime intake (per 10 g/day) 597 265 1.00 0.94 to 1.07 577 141 0.93 0.84 to 1.04 
   P value   0.9    0.2  
   Current intake (per 10 g/day) 597 265 0.97 0.91 to 1.04 577 141 0.91 0..82 to 1.01 
   P value   0.4    0.08  
      Lifetime abstention 152 68 Reference  148 38 Reference  
      Former drinkers 63 28 1.02 0.64 to 1.64 62 18 1.15 0.63 to 2.10 
      >0-19 g/day 229 101 0.92 0.66 to 1.28 218 53 0.86 0.55 to 1.34 
      20-39 g/day 90 40 0.93 0.60 to 1.43 87 21 0.84 0.47 to 1.52 
      ≥40 g/day 63 28 0.89 0.55 to 1.46 62 11 0.61 0.29 to 1.26 
      P for trendb   0.6    0.2  
   Age 20-29 intake (per 10 g/day) 597 265 1.03 0.97 to 1.09 577 141 0.97 0.89 to 1.07 
   P value   0.4    0.6  
   Age 30-39 intake (per 10 g/day) 597 265 1.00 0.95 to 1.06 577 141 0.97 0.89 to 1.05 
   P value   0.9    0.4  
   Age 40-49 intake (per 10 g/day) 597 265 1.01 0.95 to 1.06 577 141 0.95 0.87 to 1.03 
   P value   0.9    0.2  
Cigarette smoking           
   Smoking status         
      Never 313 124 Reference  306 73 Reference  
      Ever 284 141 1.25 0.95 to 1.63 271 68 1.11 0.77 to 1.60 
      P for trend   0.1    0.6  
   Smoking status         
      Never 313 124 Reference  306 73 Reference  
      Former 228 112 1.20 0.91 to 1.59 217 56 1.15 0.78 to 1.68 
      Current 56 29 1.45 0.94 to 2.24 54 12 0.97 0.51 to 1.85 
   Number of cigarettes per day         
      0 313 124 Reference  306 73 Reference  
      1-10  95 43 1.12 0.78 to 1.61 90 25 1.24 0.77 to 1.99 
      11-20 112 59 1.39 1.00 to 1.94 109 28 1.13 0.71 to 1.79 
      ≥21 73 38 1.30 0.87 to 1.95 69 15 0.94 0.51 to 1.71 
      Unknown 4 1 -  3 0 -  
      P for trend   0.07    0.9  
   Duration of smoking (years)           
      0 313 124 Reference  306 73 Reference  
      >0-15 57 26 1.25 0.81 to 1.94 54 17 1.48 0.86 to 2.55 
      16-30 96 45 1.17 0.81 to 1.69 92 19 0.84 0.49 to 1.44 
      ≥31 131 70 1.30 0.94 to 1.78 125 32 1.15 0.74 to 1.81 
      P for trend   0.1    0.8  
   Time since quitting (years)c         
      <10  56 24 Reference  54 9 Reference  
      ≥10 172 88 1.45 0.90 to 2.34 163 47 2.05 0.98 to 4.26 
      P for trend   0.1    0.06  
Physical activity         
   Physical activity score          
      0 108 56 Reference  102 29 Reference  
      >0-3.9 91 38 0.94 0.61 to 1.44 88 19 0.97 0.54 to 1.76 
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      ≥4-5.9 256 109 0.96 0.68 to 1.36 250 60 1.06 0.66 to 1.71 
      ≥6 142 62 0.95 0.64 to 1.40 137 33 1.09 0.64 to 1.86 
      P for trend   0.8    0.5  
   Exercising            
      Non-exercisers 326 146 Reference  313 79 Reference  
      Exercisers 271 119 0.94 0.73 to 1.21 264 62 0.96 0.68 to 1.36 
     P for trend   0.6    0.8  
   Walkingd          
      Non-walkers 108 56 Reference  102 29 Reference  
      Walkers 412 178 1.03 0.74 to 1.43 398 91 1.07 0.68 to 1.69 
      P for trend   0.9    0.8  
Body size          
   BMI (per 5 kg/m2) 597 265 1.16 1.00 to 1.36 577 141 1.16 0.95 to 1.42 
   P value   0.05    0.2  
      Normal 185 75 Reference  176 36 Reference  
      Overweight 283 134 1.27 0.94 to 1.71 275 70 1.29 0.85 to 1.97 
      Obese 129 56 1.20 0.83 to 1.73 126 35 1.32 0.80 to 2.16 
      P for trend   0.2    0.2  
   Waist circumferencee (per 10 cm)  597 265 1.22 1.08 to 1.37 577 141 1.27 1.08 to 1.48 
   P value   0.001    0.003  
      Healthy 231 93 Reference  220 45 Reference  
      Action levels 366 172 1.34 1.03 to 1.74 357 96 1.51 1.04 to 2.18 
      P for trend   0.03    0.03  
*Pre-existing illness defined as myocardial infarction, stroke, angina and diabetes mellitus. 
aAdjusted for age at diagnosis, year of diagnosis, sex and country of birth in addition to the 
exposures shown in table. 
bCalculated excluding former drinkers.  
cIncludes only former smokers. 
dPeople who only reported exercising were excluded.  
eWaist circumference categorized as healthy (<94 cm for males; <80 cm for females) and 
action levels (≥94 cm for males; ≥80 cm for females). 
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Table A2. Hazard ratios (HR) and 95% confidence intervals (CI) for overall and CRC-specific mortality by alcohol intake, cigarette smoking, 
physical activity, exercise, walking, BMI and waist circumference, by AJCC stage  
 Stage I Stage II Stage III P for interaction 
HRa  95% CI HRa 95% CI HRa 95% CI  
Overall mortality        
Lifetime alcohol intake (per 10 g/day) 1.11 1.01 to 1.22 1.01 0.92 to 1.12 0.99 0.91 to 1.08 0.2 
Ever smokers 1.14 0.69 to 1.89 1.27 0.85 to 1.90 1.40 0.98 to 2.00 0.8 
Physical activity score ≥4 0.89 0.53 to 1.47 0.87 0.58 to 1.30 1.11 0.76 to 1.63 0.6 
Exercisers 0.97 0.59 to 1.60 0.60 0.39 to 0.90 0.92 0.65 to 1.30 0.2 
Walkersb 0.68 0.38 to 1.21 0.73 0.46 to 1.16 1.79 1.07 to 3.00 0.01 
BMI (per 5 kg/m2) 1.18 0.88 to 1.59 1.17 0.91 to 1.50 1.17 0.96 to 1.43 0.9 
Waist circumference (per 10 cm)  1.24 1.01 to 1.52 1.26 1.06 to 1.50 1.13 0.97 to 1.30 0.5 
        
CRC-specific mortality        
Lifetime alcohol intake (per 10 g/day) 1.12 0.94 to 1.34 0.94 0.78 to 1.13 0.98 0.87 to 1.09 0.3 
Ever smokers 1.30 0.45 to 3.70 1.40 0.71 to 2.76 1.38   0.90 to 2.11 0.9 
Physical activity score ≥4 0.84 0.30 to 2.40 0.91 0.46 to 1.79 1.17 0.74 to 1.84 0.8 
Exercisers 0.88 0.31 to 2.49 0.25 0.10 to 0.60 0.98 0.65 to 1.46 0.01 
Walkersb 0.70 0.21 to 2.33 0.71 0.34 to 1.47 1.82 0.96 to 3.44 0.1 
BMI (per 5 kg/m2) 1.70 0.94 to 3.05 1.16 0.77 to 1.74 1.21 0.96 to 1.53 0.5 
Waist circumference (per 10 cm)  1.92 1.23 to 2.99 1.29 0.98 to 1.70 1.20 1.00 to 1.43 0.1 
BMI, body mass index. 
aAdjusted for age at diagnosis, year of diagnosis, sex, country of birth, degree of differentiation and anatomic site in addition to the exposures shown in the 
table. 
bPeople who only reported exercising were excluded. 
 
 
 
 
 
 
 
 
 
 
 
35 
 
Table A3. Hazard ratios (HR) and 95% confidence intervals (CI) for overall and disease-specific mortality by alcohol intake, cigarette smoking, 
physical activity, exercise, walking, BMI and waist circumference, by anatomic site  
 Colon Rectum P for interaction 
HRa  95% CI HRa 95% CI  
Overall mortality      
Lifetime alcohol intake (per 10 g/day) 1.04 0.98 to 1.12 1.00 0.92 to 1.09 0.4 
Ever smokers 1.51 1.13 to 2.03 1.05 0.73 to 1.51 0.1 
Physical activity score ≥4 0.98 0.73 to 1.33 0.91 0.63 to 1.31 0.7 
Exercisers 0.72 0.54 to 0.95 1.09 0.76 to 1.55 0.08 
Walkersb 0.99 0.68 to 1.44 0.90 0.59 to 1.37 0.7 
BMI (per 5 kg/m2) 1.05 0.89 to 1.24 1.31 1.04 to 1.64 0.1 
Waist circumference (per 10 cm)  1.14 1.01 to 1.29 1.26 1.07 to 1.47 0.3 
      
Disease-specific mortality      
Lifetime alcohol intake (per 10 g/day) 1.04 0.93 to 1.15 0.93 0.82 to 1.06 0.2 
Ever smokers 1.50 0.97 to 2.31 1.16 0.73 to 1.85 0.4 
Physical activity score ≥4 1.20 0.75 to 1.93 1.02 0.63 to 1.64 0.6 
Exercisers 0.61 0.39 to 0.94 1.22 0.77 to 1.94 0.03 
Walkersb 1.39 0.74 to 2.59 0.84 0.49 to 1.46 0.2 
BMI (per 5 kg/m2) 1.10 0.87 to 1.39 1.35 1.01 to 1.80 0.3 
Waist circumference (per 10 cm)  1.22 1.03 to 1.46 1.32 1.07 to 1.62 0.6 
BMI, body mass index. 
aAdjusted for age at diagnosis, year of diagnosis, sex, country of birth, American Joint Committee on Cancer stage and degree of differentiation in addition 
to the exposures shown in the table. 
bPeople who only reported exercising were excluded. 
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Table A4. Hazard ratios (HR) and 95% confidence intervals (CI) for overall and CRC-specific mortality by alcohol intake, cigarette smoking, 
physical activity, exercise, walking, BMI and waist circumference, by tumor molecular subtype  
 
  BRAF wild-type  BRAF mutated   KRAS wild-type KRAS mutated  
 HRa  95% CI HRa 95% CI P for interaction  HRa  95% CI HRa  95% CI P for interaction 
Overall mortality           
Lifetime alcohol intake (per 10 g/day) 1.02 0.96 to 1.09 1.16 0.97 to 1.39 0.2  1.03 0.95 to 1.11 1.04 0.94 to 1.14 0.9 
Ever smokers 1.01 0.74 to 1.38 1.82 0.99 to 3.36 0.08  1.20 0.87 to 1.66 1.00 0.59 to 1.68 0.5 
Physical activity score ≥4 1.08 0.80 to 1.46 0.95 0.51 to 1.78 0.7  0.95 0.69 to 1.30 1.45 0.83 to 2.51 0.2 
Exercisers 0.89 0.66 to 1.20 0.65 0.35 to 1.20 0.4  0.78 0.57 to 1.07 1.06 0.64 to 1.75 0.3 
Walkersc 1.09 0.77 to 1.55 0.86 0.40 to 1.87 0.6  1.11 0.77 to 1.59 0.93 0.46 to 1.86 0.7 
BMI (per 5 kg/m2) 1.17 0.97 to 1.42 1.14 0.78 to 1.66 0.9  1.20 0.99 to 1.47 1.07 0.78 to 1.47 0.5 
Waist circumference (per 10 cm)  1.14 0.99 to 1.30 1.28 0.99 to 1.66 0.4  1.17 1.01 to 1.34 1.15 0.92 to 1.43 0.9 
           
CRC-specific mortality           
Lifetime alcohol intake (per 10 g/day) 0.99 0.90 to 1.10 1.09 0.85 to 1.39 0.5  1.01 0.89 to 1.13 0.99 0.86 to 1.14 0.9 
Ever smokers 1.02 0.65 to 1.59 2.18 0.92 to 5.17 0.1  1.15 0.73 to 1.83 1.27 0.62 to 2.59 0.8 
Physical activity score ≥4 1.15 0.75 to 1.76 1.04 0.42 to 2.54 0.8  0.93 0.59 to 1.47 1.90 0.85 to 4.23 0.1 
Exercisers 0.77 0.50 to 1.18 0.69 0.29 to 1.64 0.8  0.61 0.38 to 0.98 1.23 0.62 to 2.42 0.1 
Walkersc 1.12 0.68 to 1.82 1.56 0.44 to 5.52 0.6  1.21 0.72 to 2.03 1.07 0.40 to 2.89 0.8 
BMI (per 5 kg/m2) 1.26 0.98 to 1.62 1.06 0.61 to 1.84 0.6  1.33 1.01 to 1.75 1.01  0.67 to 1.52 0.3 
Waist circumference (per 10 cm)  1.23 1.02 to 1.49 1.20 0.84 to 1.70 0.9  1.25 1.03 to 1.53 1.18 0.88 to 1.58 0.7 
BMI, body mass index. 
aAdjusted for age at diagnosis, year of diagnosis, sex and  country of birth in addition to the exposures shown in the table. 
bPeople who only reported exercising were excluded. 
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Table A5. Hazard ratios (HR) and 95% confidence intervals (CI) for overall and CRC-specific mortality by alcohol intake, cigarette smoking, 
physical activity, exercise, walking, BMI and waist circumference, by tumor molecular subtype  
 
  BRAF wild-type  BRAF mutated P for interaction KRAS wild-type KRAS mutated P for interaction 
HRa  95% CI HRa 95% CI  HRa  95% CI HRa  95% CI  
Overall mortality         
Lifetime alcohol intake (per 10 g/day) 1.01 0.94 to 1.08 1.15 0.97 to 1.38 0.2 1.01 0.94 to 1.09 1.05 0.95 to 1.16 0.5 
Ever smokers 1.03 0.75 to 1.42 2.10 1.14 to 3.89 0.04 1.27 0.92 to 1.76 0.99 0.58 to 1.68 0.4 
Physical activity score ≥4 1.09 0.80 to 1.48 0.85 0.45 to 1.61 0.5 0.94 0.68 to 1.30 1.41 0.81 to 2.46 0.2 
Exercisers 0.92 0.68 to 1.24 0.57 0.30 to 1.05 0.2 0.75 0.55 to 1.04 1.12 0.67 to 1.86 0.2 
Walkersb 1.19 0.83 to 1.70 0.77 0.35 to 1.68 0.3 1.14 0.79 to 1.66 1.00 0.49 to 2.01 0.7 
BMI (per 5 kg/m2) 1.22 1.01 to 1.47 1.03 0.72 to 1.49 0.4 1.21 0.99 to 1.47 1.08 0.77 to 1.51 0.6 
Waist circumference (per 10 cm)  1.17 1.02 to 1.35 1.19 0.92 to 1.54 0.9 1.17 1.02 to 1.35 1.19 0.94 to 1.49 0.9 
         
CRC-specific mortality         
Lifetime alcohol intake (per 10 g/day) 0.98 0.89 to 1.09 1.08 0.85 to 1.39 0.5 0.97 0.86 to 1.09 1.04 0.90 to 1.21 0.5 
Ever smokers 1.09 0.70 to 1.70 2.68 1.12 to 6.39 0.06 1.29 0.81 to 2.06 1.29 0.63 to 2.64 0.9 
Physical activity score ≥4 1.10 0.71 to 1.71 0.81 0.32 to 2.02 0.5 0.84 0.53 to 1.34 1.85 0.82 to 4.18 0.09 
Exercisers 0.77 0.50 to 1.19 0.52 0.22 to 1.27 0.4 0.56 0.35 to 0.90 1.29 0.65 to 2.58 0.05 
Walkersb 1.17 0.71 to 1.93 1.13 0.31 to 4.09 0.9 1.17 0.68 to 2.01 1.13 0.42 to 3.05 0.9 
BMI (per 5 kg/m2) 1.33 1.03 to 1.71 0.85 0.50 to 1.43 0.1 1.31 1.01 to 1.72 1.02  0.66 to 1.58 0.3 
Waist circumference (per 10 cm)  1.32 1.09 to 1.59 1.00 0.70 to 1.41 0.2 1.25 1.03 to 1.52 1.30 0.94 to 1.79 0.8 
BMI, body mass index. 
aAdjusted for age at diagnosis, year of diagnosis, sex, country of birth, American Joint Committee on Cancer stage, degree of differentiation and anatomic site in addition to 
the exposures shown in the table. 
bPeople who only reported exercising were excluded. 
 
 
 
